TRIAL WATCH PCSK9 antibody reduces LDL cholesterol

被引：30
|
作者：
Crunkhorn, Sarah
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 01期
关键词：
D O I：
10.1038/nrd3633
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [31] PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. John Betteridge
    Nature Reviews Endocrinology, 2013, 9 : 76 - 78
  • [32] The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
    Piper, Derek E.
    Jackson, Simon
    Liu, Qiang
    Romanow, William G.
    Shetterly, Susan
    Thibault, Stephen T.
    Shan, Bei
    Walker, Nigel P. C.
    STRUCTURE, 2007, 15 (05) : 545 - 552
  • [33] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [34] Plasma PCSK9 preferentially reduces liver LDL receptors in mice
    Grefhorst, Aldo
    McNutt, Markey C.
    Lagace, Thomas A.
    Horton, Jay D.
    JOURNAL OF LIPID RESEARCH, 2008, 49 (06) : 1303 - 1311
  • [35] PCSK9 inhibitors for LDL lowering
    Walsh, Lames P.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 575 - 577
  • [36] PCSK9 and atherosclerosis: beyond LDL
    Catapano, A. L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 28 - 28
  • [37] Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease
    Folsom, Aaron R.
    Peacock, James M.
    Boerwinkle, Eric
    ATHEROSCLEROSIS, 2009, 202 (01) : 211 - 215
  • [38] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [39] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [40] Evolocumab (Repatha) A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 139 - 140
12345